Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin Diseases AND Skin Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,923 result(s) found for: Skin Diseases AND Skin Disease. Displaying page 40 of 97.
    «« First « Previous 36  37  38  39  40  41  42  43  44  Next» Last»»
    EudraCT Number: 2017-002581-51 Sponsor Protocol Number: AK002-006 Start Date*: 2018-01-10
    Sponsor Name:Allakos Inc.
    Full Title: An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria
    Medical condition: Patients with different types of chronic urticaria resistant to standard dose antihistamines
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005092-14 Sponsor Protocol Number: GT-24 Start Date*: 2013-03-12
    Sponsor Name:ALK-Abelló S.A.
    Full Title: Molecular and Cellular Mechanism in the course of Immunotherapy with a Phleum pratense oral lyophilisate
    Medical condition: Treatment of grass pollen induced rhinitis and conjunctivitis in adult patients with clinically relevant symptoms and diagnosed witha positive skin-prick test and / or specific IgE test to grass po...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004855 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004669-16 Sponsor Protocol Number: C2501004 Start Date*: 2019-09-23
    Sponsor Name:Pfizer Inc
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
    Medical condition: Moderate to severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001368-40 Sponsor Protocol Number: M-41008-41 Start Date*: 2017-09-13
    Sponsor Name:Almirall S.A.
    Full Title: Open clinical study to assess long-term efficacy and safety of dimethyl fumarate in adults with moderate to severe chronic plaque psoriasis in real practice (DIMESKIN 1 Trial)
    Medical condition: Moderate-severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005388-30 Sponsor Protocol Number: T525-STD-043 Start Date*: 2022-11-21
    Sponsor Name:Inmunotek, S.L.
    Full Title: Quercus ilex and Quercus robur allergenic extracts. Determination of the in vivo allergenic potency in histamine equivalent units (HEP).
    Medical condition: Allergy to Quercus ilex and Quercus robur pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023757-11 Sponsor Protocol Number: myDC/pDCinstageIIImelanoma Start Date*: 2014-11-06
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Myeloid and plasmacytoid blood dendritic cells for immunotherapy of stage III melanoma patients scheduled for radical lymph node dissection
    Medical condition: melanoma patients with regional lymph node metastases (stage III)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002255-42 Sponsor Protocol Number: MK-3222-010 Start Date*: 2013-01-10
    Sponsor Name:Sun Pharma Global FZE
    Full Title: A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optiona...
    Medical condition: Moderate-to-Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-000284-48 Sponsor Protocol Number: EDP1815-208 Start Date*: 2022-06-06
    Sponsor Name:EVELO Biosciences Inc
    Full Title: A Long-Term Extension Trial in participants with Atopic Dermatitis who participated in previous Phase 2 and 3 EDP1815 trials
    Medical condition: Mild, moderate, and severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006885-19 Sponsor Protocol Number: ARQ-151-313 Start Date*: Information not available in EudraCT
    Sponsor Name:Arcutis Biotherapeutics, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003567-22 Sponsor Protocol Number: Zincox12 Start Date*: 2012-12-05
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: Efficacy of topical application of zinc oxide ointment compared with zinc oxide paste and tocoferol, for treating diaper dermatitis in infant: a randomized, controlled, triple blind study
    Medical condition: Diaper dermatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012444 Dermatitis diaper PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004750-39 Sponsor Protocol Number: LEOSIC Start Date*: 2022-07-08
    Sponsor Name:Herlev Gentofte Hospital - Department of Dermatology and Allergy
    Full Title: The role of Interleukin-1B targeted therapy for patients suffering with allergic contact dermatitis: A randomized controlled trial with Anakinra vs. Placebo.
    Medical condition: Allergic contact dermatitis. Patients with nickel allergy to be specific
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10056265 Allergic contact dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005389-32 Sponsor Protocol Number: T521-STD-044 Start Date*: 2023-03-13
    Sponsor Name:Inmunotek, S.L.
    Full Title: Juniperus oxycedrus and Cupressus arizonica allergen extracts. Determination of the in vivo allergenic potency in histamine equivalent units (HEP).
    Medical condition: Allergy to Cupressaceae: Juniperus oxycedrus and Cupressus arizonica
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-005083-34 Sponsor Protocol Number: CAPI2017NL10 Start Date*: 2017-08-23
    Sponsor Name:University Medical Center Utrecht
    Full Title: Conestat alfa as prophylactic treatment for idiopathic non-histaminergic acquired angioedema
    Medical condition: The medical condition to be investigated is idiopathic non-histaminergic angioedema (InH-AAE). This disease is characterized by recurrent episodes with swelling of the subcutis and mucous membranes...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001353-16 Sponsor Protocol Number: BAY63-2521/16277 Start Date*: 2015-04-17
    Sponsor Name:Bayer AG
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
    Medical condition: diffuse cutaneous systemic sclerosis (dcSSc)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004705-26 Sponsor Protocol Number: LPS15497 Start Date*: 2020-03-24
    Sponsor Name:Sanofi Aventis Groupe
    Full Title: A randomized double blind placebo controlled study evaluating the effect of dupilumab on sleep in adult patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002513-36 Sponsor Protocol Number: ASP-1929-301 Start Date*: 2019-08-16
    Sponsor Name:Rakuten Aspyrian, Inc.
    Full Title: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck ...
    Medical condition: Locoregional, recurrent head and neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GR (Completed) BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001136-21 Sponsor Protocol Number: B7451013 Start Date*: 2018-10-22
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with M...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) CZ (Completed) GB (Completed) DE (Completed) PL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2005-005450-45 Sponsor Protocol Number: P04684 Start Date*: 2006-08-30
    Sponsor Name:Schering-Plough Research Institute
    Full Title: Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/ Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Mee...
    Medical condition: Persistent Allergic Rhinitis (Allergic Rhinitis)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039085 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) ES (Completed) DE (Completed) HU (Completed) SE (Completed) GR (Completed) DK (Completed) IT (Completed) BE (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003200-39 Sponsor Protocol Number: 13/0077 Start Date*: 2014-04-01
    Sponsor Name:University College London
    Full Title: A phase II, single centre, randomised, placebo-controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma
    Medical condition: Renal complications of systemic sclerosis (scleroderma renal crisis and chronic kidney disease).
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10061087 Connective tissue disorder PT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10018124 Generalized scleroderma LLT
    16.1 100000004857 10069339 Acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001765-25 Sponsor Protocol Number: CASM981CUS09 Start Date*: 2017-09-28
    Sponsor Name:Novartis
    Full Title: An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Doubleblind Vehicle Controlled Phase to Evaluate Effects on Atopic De...
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 36  37  38  39  40  41  42  43  44  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 06:46:23 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA